Compare FCCO & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FCCO | TLSI |
|---|---|---|
| Founded | 1994 | 2010 |
| Country | United States | United States |
| Employees | N/A | 102 |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 290.5M | 270.2M |
| IPO Year | 2012 | N/A |
| Metric | FCCO | TLSI |
|---|---|---|
| Price | $30.07 | $3.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 61.4K | ★ 715.2K |
| Earning Date | 04-22-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.16% | N/A |
| EPS Growth | ★ 36.46 | N/A |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $922,000.00 | N/A |
| Revenue This Year | $30.67 | $35.45 |
| Revenue Next Year | $5.87 | $37.58 |
| P/E Ratio | $51.02 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $21.80 | $2.20 |
| 52 Week High | $31.51 | $7.95 |
| Indicator | FCCO | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 52.26 | 43.67 |
| Support Level | $29.16 | $2.20 |
| Resistance Level | $31.21 | $4.63 |
| Average True Range (ATR) | 0.67 | 0.39 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 56.64 | 47.63 |
First Community Corp is a bank holding company. Along with its subsidiaries, it provides various banking products and services for professionals and small and medium-sized businesses, including consumer and commercial banking, mortgage, brokerage and investment, online banking, and insurance services. The company offers checking, savings, money market, individual retirement, and certificates of deposit accounts, and its lending lines include consumer loans, real estate loans, home improvement loans, home loans, flex loans, construction loans, agricultural loans, and others. The company's reportable segments are: Commercial and Retail Banking, which derives maximum revenue; Mortgage Banking; Investment Advisory and Non-Deposit; and Corporate.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.